SLC5A2 and early-onset autosomal dominant Alzheimer disease: SGLT2 inhibitors can possibly bring benefits in patients with Alzheimer’s Disease using the abovementioned mechanisms, including not only anti-inflammatory, anti-oxidative or atheroprotective effects, but also direct neuroprotective effects including BDNF increase and AChE inhibition.